Proposal for a national diagnostics action plan for the United States.

Publication date: Dec 15, 2023

Providing a definitive diagnostic test in a disease emergency is critical to limit pathogen spread, develop and deploy medical countermeasures, and mitigate the social and economic harms of a serious epidemic. While major accomplishments have accelerated test development, expanded laboratory testing capacity, and established widespread point-of-care testing, the United States does not have a plan to rapidly respond, to develop, manufacture, deploy, and sustain diagnostic testing at a national scale. To address this gap, we are proposing a National Diagnostics Action Plan that describes the steps that are urgently needed to prepare for future infectious disease emergencies, as well as the actions we must take at the first signs of such’ events. These recommendations require substantial collaboration between the US government (USG) and the private sector to solve a series of challenges now, as well as to prepare for the massive and rapid scale-up of laboratory and point-of-care test development and testing capacity in future emergencies. The recommendations include establishing pre-event contracts; ensuring rapid access to clinical samples; creating a permanent public-private testing coordinating body to allow for rapid information sharing and improved cooperation among the USG, test developers, and clinical laboratories; and accelerating testing rollout at the beginning of an event-and thus, the effective public health management of a disease crisis.

Open Access PDF

Concepts Keywords
Countermeasures COVID-19 response
Epidemic Diagnostic testing
Epidemiology Laboratory testing
Expanded Mpox
Laboratory Pandemic preparedness


Type Source Name
disease MESH emergency
disease IDO pathogen
disease VO Gap
disease MESH infectious disease
pathway REACTOME Infectious disease
disease VO effective
drug DRUGBANK Coenzyme M
disease MESH COVID19
disease VO volume
disease IDO process
disease MESH monkeypox
disease MESH uncertainty
drug DRUGBANK L-Valine
disease IDO production
drug DRUGBANK Trestolone
disease IDO country
drug DRUGBANK Ranitidine
drug DRUGBANK L-Phenylalanine
drug DRUGBANK Clotiazepam
disease VO time
drug DRUGBANK Telbivudine
disease VO efficient
disease VO efficiency
drug DRUGBANK Amlodipine
drug DRUGBANK Huperzine B
disease VO protocol
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Etoperidone
disease VO Equity
disease VO inefficient
disease MESH hepatitis
disease VO LACK
disease IDO facility
disease VO USDA
disease VO company
drug DRUGBANK Ademetionine
disease VO organization
disease MESH emerging infectious disease
disease VO laboratory test
disease IDO emerging pathogen
disease VO report
drug DRUGBANK Serine
drug DRUGBANK Methylphenidate
disease VO NAP

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *